相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Design, synthesis and biological evaluation of imidazole and triazole-based carbamates as novel aromatase inhibitors
Alessandra Ammazzalorso et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Lowell L. Hart et al.
ADVANCES IN THERAPY (2021)
Synthesis, biological evaluation, and docking study of indole aryl sulfonamides as aromatase inhibitors
Marialuigia Fantacuzzi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Aromatase inhibitors: Role in postmenopausal breast cancer
Rajeev Kharb et al.
ARCHIV DER PHARMAZIE (2020)
Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs
Niall A. Anderson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Overcoming Endocrine Resistance in Breast Cancer
Ariella B. Hanker et al.
CANCER CELL (2020)
Discovery of a novel series of imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors
Chen Shi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Xin Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
PROTAC Technology: Opportunities and Challenges
Hongying Gao et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents
Brilliant N. Marak et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
CDK4/6 and MAPK-Crosstalk as Opportunity for Cancer Treatment
Lisa Scheiblecker et al.
PHARMACEUTICALS (2020)
Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders
Christian Steinebach et al.
CHEMICAL SCIENCE (2020)
Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Neil Portman et al.
ENDOCRINE-RELATED CANCER (2019)
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6
Baishan Jiang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Selective degradation of CDK6 by a palbociclib based PROTAC
Sandeep Rana et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, invitro and in human tumor xenograft models
Fei Long et al.
CANCER SCIENCE (2019)
CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors
Meiyang Xi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Properties of FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Classifying Breast Cancer Subtypes Using Multiple Kernel Learning Based on Omics Data
Mingxin Tao et al.
GENES (2019)
Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo
Yudi Xiong et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Selective oestrogen receptor degraders in breast cancer: a review and perspectives
Andrea Gombos
CURRENT OPINION IN ONCOLOGY (2019)
Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib
Melania Poratti et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer
Chen Shi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Synthesis and anticancer activity of some pyrido[2,3-d]pyrimidine derivatives as apoptosis inducers and cyclin-dependent kinase inhibitors
Safinaz E-S Abbas et al.
FUTURE MEDICINAL CHEMISTRY (2019)
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
Shang Su et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
Antoinette R. Tan et al.
LANCET ONCOLOGY (2019)
Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer
Vassilis Aggelis et al.
DRUGS (2019)
CDK9 as an Appealing Target for Therapeutic Interventions
Shirin Eyvazi et al.
CURRENT DRUG TARGETS (2019)
Recent advances in the development of cyclin-dependent kinase 7 inhibitors
Yuou Teng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML
Matthias Brand et al.
CELL CHEMICAL BIOLOGY (2019)
Mechanistic Insight of Cyclin-Dependent Kinase 5 in Modulating Lung Cancer Growth
G. M. Shazzad Hossain Prince et al.
CHINESE JOURNAL OF PHYSIOLOGY (2019)
Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma
Zsofia Czudor et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships
Yan Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents
Solomon Tadesse et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
The Emerging Picture of CDK11: Genetic, Functional and Medicinal Aspects
Nikolas Ferreira dos Santos Paparidis et al.
CURRENT MEDICINAL CHEMISTRY (2018)
Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy
Chuantao Zha et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
Filipa Lynce et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8
John M. Hatcher et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors
Hui Zhao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Shom Goel et al.
TRENDS IN CELL BIOLOGY (2018)
CDK4/6 inhibition in breast cancer: current practice and future directions
Sonia Pernas et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Hai-Tsang Huang et al.
CELL CHEMICAL BIOLOGY (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors
Sourav Kalra et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors
Solomon Tadesse et al.
FUTURE MEDICINAL CHEMISTRY (2017)
Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation
Solomon Tadesse et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
Jiayuan Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Structural basis of PROTAC cooperative recognition for selective protein degradation
Morgan S. Gadd et al.
NATURE CHEMICAL BIOLOGY (2017)
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
Shenghui He et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
John E. Bisi et al.
ONCOTARGET (2017)
Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors
Yan Fu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Selective small-molecule inhibitors as chemical tools to define the roles of matrix metalloproteinases in disease
Jayda E. Meisel et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2017)
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)
Caroline M. Robb et al.
CHEMICAL COMMUNICATIONS (2017)
Small-Molecule PROTACS: New Approaches to Protein Degradation
Momar Toure et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Synthesis and biological characterization of 3-(imidazol-1-ylmethyl) piperidine sulfonamides as aromatase inhibitors
Mauro Di Matteo et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
John E. Bisi et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Ping Chen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik et al.
CANCER DISCOVERY (2016)
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Julia A. Beaver et al.
CLINICAL CANCER RESEARCH (2015)
Pyrazoloquinazolines: Synthetic strategies and bioactivities
Mansi Garg et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
A historical overview of protein kinases and their targeted small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2015)
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Marion Peyressatre et al.
CANCERS (2015)
Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts
Sonya C. Tate et al.
CLINICAL CANCER RESEARCH (2014)
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
Mohammad Hojjat-Farsangi
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert et al.
INVESTIGATIONAL NEW DRUGS (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Cyclin-dependent kinases
Marcos Malumbres
GENOME BIOLOGY (2014)
Small-Molecule Regulators of Autophagy and Their Potential Therapeutic Applications
Mi Zhou et al.
CHEMMEDCHEM (2013)
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
JulieAnn Rader et al.
CLINICAL CANCER RESEARCH (2013)
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
Prithviraj Bose et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure-Activity Relationship, and Anticancer Activities
Hao Shao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
The molecular basis of targeting protein kinases in cancer therapeutics
Chung-Jung Tsai et al.
SEMINARS IN CANCER BIOLOGY (2013)
Novel Aromatase Inhibitors by Structure-Guided Design
Debashis Ghosh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
K. A. Blum et al.
LEUKEMIA (2011)
Targeting the Undruggable Proteome: The Small Molecules of My Dreams
Craig M. Crews
CHEMISTRY & BIOLOGY (2010)
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
Christophe Le Tourneau et al.
EUROPEAN JOURNAL OF CANCER (2010)
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Cyclin-dependent kinases: a family portrait
Marcos Malumbres et al.
NATURE CELL BIOLOGY (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Aromatase inhibitors: past, present and future in breast cancer therapy
Udayan Dutta et al.
MEDICAL ONCOLOGY (2008)
Selective estrogen-receptor modulators and antihormonal resistance in breast cancer
V. Craig Jordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The molecular portraits of breast tumors are conserved across microarray platforms
Zhiyuan Hu et al.
BMC GENOMICS (2006)
Discovery and evaluation of dual CDK1 and CDK2 inhibitors
M Payton et al.
CANCER RESEARCH (2006)
分享论文
